Megapaloju (Palonosetron Hydrochloride)

Adult administration

Adults 1) Prevention of nausea and vomiting induced by antineoplastic chemotherapy: Administer palonosetron 0.25 mg once by intravenous injection over at least 30 seconds, 30 minutes before the start of chemotherapy. 2) Prevention of postoperative nausea and vomiting: Administer 0.075 mg once by intravenous injection over at least 10 seconds, immediately before induction of anesthesia. As with other antiemetics, routine administration is not recommended for patients expected to have a low likelihood of postoperative nausea and vomiting. Administration of this drug is recommended for patients in whom postoperative nausea and vomiting must be avoided, even if the likelihood of postoperative nausea and vomiting is low. 3) Treatment of postoperative nausea and vomiting: Administer 0.075 mg once by intravenous injection over at least 10 seconds as soon as nausea and vomiting occur. No dosage adjustment is required for elderly patients or patients with hepatic or renal impairment. There are no clinical data for patients with end-stage renal disease undergoing dialysis. This drug must not be mixed with other drugs. Flush the infusion line with normal saline before and after administration of this drug.

Child administration

Children (2 months and older) 2 months and older: Prevention of acute nausea and vomiting induced by antineoplastic chemotherapy: Administer palonosetron 0.02mg/kg (maximum 1.5mg) once by intravenous infusion over at least 15 minutes, 30 minutes before the start of chemotherapy. Neonates: The safety and efficacy of this drug have not been established (no data are available). Infants (under 24 months): Data on the use of this drug for the prevention of nausea and vomiting induced by antineoplastic chemotherapy are limited.

This drug should not be administered to patients who have a hypersensitivity to this drug or its components. Patients who have had hypersensitivity reactions to other selective 5-HT3 receptor antagonists should be cautious as similar reactions may occur with this drug. Since this drug may slow bowel movements, patients with a history of constipation or those with symptoms of intestinal obstruction need to be carefully monitored when administered. Patients taking other serotonergic medications such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) should be observed closely due to the risk of serotonin syndrome. This drug is used to prevent nausea and vomiting induced by chemotherapy or to alleviate postoperative nausea and vomiting, and may have side effects such as headache, constipation, diarrhea, dizziness, and fatigue. Rare cardiovascular side effects reported include arrhythmias or blood pressure changes, and skin rashes, pruritus, burning eyes, or dyspepsia may also occur. Caution is advised as this medication may cause dizziness, drowsiness, or fatigue when driving or operating machinery. It should be used during pregnancy only if absolutely necessary, and if breastfeeding, it should be discussed with a doctor whether to stop nursing due to the possibility of the medication being passed into breast milk. No special dosage adjustment is required for the elderly, but caution should be taken as sensitive reactions may occur. In case of overdose, there are no specific antidotes available, so appropriate treatment should be based on symptoms, and dialysis is ineffective. This drug should be stored in a sealed container to avoid exposure to air or moisture, maintaining room temperature between 1°C and 30°C. Additionally, it should be stored away from direct sunlight or strong light to maintain its effectiveness. There are few drug interactions, but caution is required when used with drugs that may prolong the QT interval. If any abnormal symptoms occur while using this medication, the healthcare provider should be notified immediately to take appropriate measures.

• Headache
• constipation
• diarrhea
• dizziness
• fatigue
• abdominal pain
• insomnia
• nonpersistent tachycardia
• bradycardia
• hypotension

This medication should be stored in a sealed container to prevent air or moisture ingress. It is important to maintain room temperature between 1°C and 30°C. Additionally, storing it away from direct sunlight or strong light is essential to preserve its effectiveness.

Appearance

A colorless, transparent solution in a colorless, transparent prefilled syringe

Package unit

1.5 mL × 5 prefilled syringes, 5 mL × 1 prefilled syringe